Overall market sentiment has been down on Assembly Biosciences Inc (ASMB) stock lately. ASMB receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With ASMB Stock Today?
Assembly Biosciences Inc (ASMB) stock is higher by 3.92% while the S&P 500 is lower by -1.86% as of 2:37 PM on Wednesday, Oct 28. ASMB has gained $0.58 from the previous closing price of $14.81 on volume of 300,414 shares. Over the past year the S&P 500 is higher by 11.90% while ASMB is lower by -1.91%. ASMB lost -$2.51 per share in the over the last 12 months.
To screen for more stocks like Assembly Biosciences Inc click here.
More About Assembly Biosciences Inc
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Click Here to get the full Stock Score Report on Assembly Biosciences Inc (ASMB) Stock.
